Pcrx

HIRASUZUKI model returns to the scene of “hard” fishing. We can safely say that this model is a turning point when it comes to making blanks… a perfect combination of stiffness and sensitivity.Its sensitive tip allows the maximum performance of the different lures in the water, as well as a great lifting power that will fully support the angler on his way to the DREAM CATCH.H model will allow us to fish from height with a wide variety of lures, keeping the control every time. This powerful design will allow us to enjoy a fight with a great sense of security.The newest technology “CROSS FORCE” Manufacturing method is also present in this blank allowing torsions from any angle during the combat. Even, being a light rod, it has an outstanding lifting power … Let’s fight! Model Length (m) Lure weight Line weight Rod weight (g) Action Guide type Nb of guides Reel seat type Reference PCRX-1102HIRA 3.35 10-55g 10-20lb / PE1-3 227 FAST FUJI ALCONITE TOP guide + 7pcs FUJI DPS PCRX-10112H 3.32 20-80g 14-30lb / PE1.5-3.5 226 FAST FUJI ALCONITE TOP guide + 10pcs FUJI DPS

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Pacira BioSciences, Inc. (PCRX) Failed to Disclose its Lack of Patent Protection for Exparel According to the complaint, during the class period, defendants created the false impression that Pacira had sufficient patent protections on Exparel (bupivacaine liposome injectable suspension), which the Company stated was critical to its future growth and revenue. In truth, Pacira knew that the ‘495 patent was not as protective as defendants publicly touted because on June 6, 2023, the New Jersey District Court issued a ruling against Pacira in its case against eVenus Pharmaceuticals for patent infringement related to Exparel. Defendants continued to make public statements affirming their belief in the ‘495 patent and the protection it provided for Exparel. Therefore, when the ‘495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira’s revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent. When Pacira announced it lost the second lawsuit against eVenus on August 9, 2024, the price of Pacira's stock fell from $22.36 per share on August 8, 2024, to $11.70 per share on August 9, 2024, a decline of over 47% in a single day. What Now: You may be eligible to participate in the class action against Pacira BioSciences, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by March 14, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a

Baseball Classic NBA News Draft Scores and schedules Standings Stats Teams Players Injuries Videos Odds Playoffs NHL News Scores and schedules Standings Stats Teams Players Odds Playoffs Soccer News Scores and schedules Premier League MLS NWSL Liga MX CONCACAF League Champions League La Liga Serie A Bundesliga Ligue 1 World Cup College football News Scores and schedules Standings Rankings Stats Teams MMA WNBA Sportsbook NCAAF Tennis Golf NASCAR NCAAB NCAAW Boxing USFL Cycling Motorsports Olympics Horse racing GameChannel Rivals Newsletters Podcasts Videos RSS Jobs Help World Cup More news Creators Games Tech Local Services Terms Privacy Privacy Dashboard Feedback © 2025 All rights reserved. Yahoo Finance Unlock stock picks and a broker-level newsfeed that powers Wall Street. NasdaqGS - Delayed Quote USD Pacira BioSciences, Inc. (PCRX) At close: 4:00:00 PM EDT After hours: 4:20:00 PM EDT Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD. NameTitlePayExercisedYear Born Ms. Kristen Williams Esq., J.D. Chief Administrative Officer & Secretary 738.52k -- 1974 Mr. David M. Stack Advisor 1.7M -- 1950 Mr. Charles A. Reinhart III, CPA, M.B.A. Executive Officer 720.29k -- 1961 Dr. Jonathan Slonin M.D. Chief Medical Officer 730.87k -- 1975 Mr. Frank D. Lee CEO & Director -- -- 1968 Mr. Shawn M. Cross Chief Financial Officer -- -- 1968 Ms. Lauren Bullaro Riker Principal Accounting Officer & Senior VP

Of Finance 288.81k 196.6k 1979 Ms. Susan Mesco Head of Investor Relations -- -- -- Mr. Anthony Molloy III, Esq. Chief Legal & Compliance Officer 581.41k 802.07k 1975 Mr. Christopher C. Young Chief Manufacturing Officer -- -- 1972 Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Pacira BioSciences, Inc.’s ISS Governance QualityScore as of March 1, 2025 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 9; Compensation: 3. Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank

Multicenter, randomized controlled study of Remedisc later this year. Troutman Pepper is acting as legal advisor to Spine BioPharma in connection with the transaction.About Degenerative Disc Disease 266 million individuals around the world have Degenerative Disc Disease, or DDD, and its associated Chronic Low Back Pain each year. DDD of the lumbar, or lower, spine is a significant cause of disability in the world and a tremendous expense to the healthcare system. It is associated with a variety of clinical symptoms, including, weakness, low back pain and disability of varying levels of severity. There is currently no treatment for the underlying cause of DDD and current approaches are aimed at managing pain through a variety of approaches that include physical therapy, chiropractic care, over the counter medications like non-steroidal anti-inflammatory drugs (NSAIDS) or prescription opioids. or patients with moderate to severe pain that persists chronically, treatment plans include epidural steroid injections, nerve blocks, radiofrequency ablation or surgical intervention. Clinical outcomes vary and often do not provide predictable benefit. Given the substantial costs, pain, and disability associated with DDD, and the current lack of an approved disease-modifying agent, a therapy that could relieve pain and increase function with the potential to mediate the progression of DDD or achieve a regenerative effect could revolutionize the standard of care. About Spine BioPharmaSpine BioPharma specializes in non-surgical therapies that will reduce pain, restore function and slow or stop pathological spinal disease progression without the use of opioids. Spine BioPharma's lead candidate, Remedisc™, is a first-in-class, therapeutic for the treatment of degenerative disc disease, offering clinical benefits of pain relief, restoration of function and potential prevention of disease progression. To learn more about Spine BioPharma, visit www.spinebiopharma.com.About Pacira BiosciencesPacira BioSciences, Inc. (NASDAQ: PCRX) is the industry leader in its commitment to non-opioid pain management and

Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.72%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.89, delivering a surprise of 21.92%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Pacira , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $167.72 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $163.93 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Pacira shares have lost about 48.8% since the beginning of the year versus the S&P 500's gain of 21.2%. While Pacira has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Pacira: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are